insights_auto
Prečo akcie IMM klesli 8,33%?
Preskúmať podrobnejšiechevron_right
IMM:ASX
Immutep Ltd
0,022 AUD
arrow_downward
-8,33%(-0,0020) 1 d.
22. 10., 16:10:29 GMT+11 · AUD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre IMM…
Otvoriť
0,02 AUD
Vysoká
0,02 AUD
Nízka
0,02 AUD
Trh. kap.
37,29 mil.
Priem. obj.
14,64 mil.
Objem
6,22 mil.
Max. za 52 týž.
0,47 AUD
Min. za 52 týž.
0,02 AUD
Výnosy na akciu
-0,05 AUD
Akcie v obehu
1,47 mld.
Počet zamestnancov
19
Otvoriť
0,02 AUD
Vysoká
0,02 AUD
Nízka
0,02 AUD
Trh. kap.
37,29 mil.
Priem. obj.
14,64 mil.
Objem
6,22 mil.
Max. za 52 týž.
0,47 AUD
Min. za 52 týž.
0,02 AUD
Výnosy na akciu
-0,05 AUD
Akcie v obehu
1,47 mld.
Počet zamestnancov
19
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
https://www.dars.gov.et/
·
pred 2 mesiacmi
Immutep (IMMP) Q2 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D Investment
Profil
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
Informácie o subjekte Immutep Ltd